Gaithersburg, MD, July 24, 2002 -- MedImmune, Inc. (Nasdaq: MEDI) announced today the appointment of Pamela J. Lupien as vice president, human resources, Edward T. Mathers as vice president, corporate development, and Lota S. Zoth as vice president and controller.
“I am pleased with the high level talent that MedImmune continues to attract and retain across the organization,” said David M. Mott, chief executive officer. “With the addition of Pam, Ed and Lota, we have added three extremely intelligent, talented and motivated professionals who I expect to contribute meaningfully to the future of the company.”
As vice president of human resources, Pamela J. Lupien is responsible for all aspects of the company's human resource function, including management of the company's strategies, policies and activities for employee recruitment and retention, compensation, benefits and management development. Ms. Lupien joins MedImmune from Orbital Sciences Corporation where she was senior vice president of human resources from 2000 until 2002. Previously she held a variety of increasingly responsible positions at James Martin & Company, Betzdearborn, Inc., Freuhauf Trailer Corporation, and IBM Corporation. Ms. Lupien has a bachelor's degree in social services from University of South Florida and a master's in business administration from Jacksonville University.
Edward T. Mathers has joined MedImmune as vice president, corporate development. He is responsible for the company's licensing and business development activities, for project management and for overseeing the legal affairs function. Mr. Mathers will also work closely with MedImmune Ventures, the company's venture capital subsidiary, to evaluate new strategic investment opportunities. Prior to joining MedImmune, Mr. Mathers was vice president of marketing and corporate licensing and acquisitions at Inhale Therapeutic Systems. Previously, he enjoyed a successful 15-year career at Glaxo Wellcome, Inc. (GlaxoSmithKline), holding a number of increasingly responsible positions in sales and marketing. Mr. Mathers started his career at Ortho Pharmaceuticals Corporation (a division of Johnson & Johnson) as a researcher. His bachelor's degree in chemistry is from North Carolina State University.
As vice president and controller, Lota S. Zoth is responsible for all accounting functions within MedImmune, including internal and external financial reporting, as well as tax planning, tax compliance, financial forecasting and financial analysis. Ms. Zoth joins MedImmune from PSINet Inc., where she was the senior vice president, corporate controller from 2000 to 2002. Starting her career in public accounting with Ernst & Young in 1982, Ms. Zoth moved to private industry in 1991 where she held a number of increasingly responsible positions covering a broad spectrum of finance and accounting functions at Pepsico, Marriott Management Services, and Sodexho Marriott Services. Ms. Zoth is a certified public accountant and has a bachelor's degree in accounting from Texas Tech University.
MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. MedImmune currently markets three products, Synagis® (palivizumab), Ethyol® (amifostine) and CytoGam® (cytomegalovirus immune globulin intravenous (human)), and has 11 products in clinical testing. MedImmune employs approximately 1,500 people, is headquartered in Gaithersburg, Maryland, and has additional operations in Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom and the Netherlands. For more information on MedImmune, visit the company's website at www.medimmune.com.
DISCLOSURE NOTICE: This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.